Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 09/6/13 → 05/24/23 |
Funding
- Novartis Pharmaceuticals Corporation: $361,107.18
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Variable Treatment Durations Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients with Secondary Progressive Multiple Sclerosis
- Coyle, Patricia (PI)
- Kowalska, Agnieszka (CoPI)
- Milazzo, Maria (CoPI)
- Krupp, Lauren (PI)
- Melville, Patricia (CoPI)
Project: Research